Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8311 to 8325 of 8990 results

  1. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

    Technology appraisal guidance
    Discontinued

  2. Nintedanib for previously treated metastatic colorectal cancer [ID1030]

    Discontinued Reference number: GID-TA10138

    Technology appraisal guidance
    Discontinued

  3. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued Reference number: GID-TA11258

    Technology appraisal guidance
    Discontinued

  4. Osteoarthritis - diacerein [ID332]

    Discontinued Reference number: GID-TAG250

    Technology appraisal guidance
    Discontinued

  5. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued Reference number: GID-TA11238

    Technology appraisal guidance
    Discontinued

  6. NGR-TNF for previously treated advanced malignant pleural mesothelioma [ID655]

    Discontinued Reference number: GID-TA10183

    Technology appraisal guidance
    Discontinued

  7. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued Reference number: GID-TA10750

    Technology appraisal guidance
    Discontinued

  8. Stye: antimicrobial prescribing

    Discontinued Reference number: GID-NG10167

    Antimicrobial prescribing guideline
    Discontinued

  9. Conjunctivitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10166

    Antimicrobial prescribing guideline
    Discontinued

  10. Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

    Discontinued Reference number: GID-TA10536

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued Reference number: GID-TA10697

    Technology appraisal guidance
    Discontinued

  12. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued Reference number: GID-TA10539

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued Reference number: GID-TA10570

    Technology appraisal guidance
    Discontinued

  14. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued

  15. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued Reference number: GID-TA11207

    Technology appraisal guidance
    Discontinued